BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2746 related articles for article (PubMed ID: 18573173)

  • 21. [The action of donor-derived NK cell in leukemic mice MHC haplotype-mismatched bone marrow transplantation].
    Wang CY; Tan H; Guo KY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):107-10. PubMed ID: 19563021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
    Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
    Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
    Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
    Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
    Hu B; Bao G; Zhang Y; Lin D; Wu Y; Wu D; Liu H
    J Immunol; 2012 Aug; 189(4):1661-70. PubMed ID: 22798668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.
    Sauter CT; Bailey CP; Panis MM; Biswas CS; Budak-Alpdogan T; Durham A; Flomenberg N; Alpdogan O
    Bone Marrow Transplant; 2013 Sep; 48(9):1237-42. PubMed ID: 23624821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
    Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
    Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
    Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 138.